Atropine IV, IM, SC, ENDOTRACHEAL
1 mini jet
To temporarily increase heart rate or decrease AV-block until definitive intervention can take place
As an antidote for inadvertent overdose of cholinergic drugs or for cholinesterase poisoning such as from organophosphorus insecticides
Atropine vials contain 600mcg in 1ml or 1200mcg in 1ml
Atropine mini-jets contain 1mg in 10ml (i.e. 100mcg/ml)
Compatible with the following IV fluids:
Dilution in IV fluids is not recommended
Atropine sulphate is stated to be compatible, when mixed in a syringe immediately before use, with the following:
Chlorpromazine Droperidol Fentanyl Glycopyrrolate
Metoclopramide Midazolam Morphine Pethidine
Prochlorperazine Promethazine Ranitidine
If the solution is cloudy, do not use.
Store at room temperature below 25°C
Bradycardia: 0.6mg IV
Organophosphate poisoning: 2mg IV then 2mg every 15 minutes until atropinised, then 0.02-0.08mg/kg/hr for several days
Endotracheal route(only if IV access cannot be obtained)
The recommended adult dose of atropine for endotracheal administration is 1 to 2 mg diluted to a total not to exceed 10 ml of sterile water or normal saline.
Note: - The administration of less than 0.5 mg can produce a paradoxical bradycardia because of the central or peripheral parasympathomimatic effects of low dose in adults.
DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose as in normal renal function
Atropine is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however, it is termed an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters.
There are no absolute contraindications to atropine. However, atropine is relatively contraindicated in:
In adults, the administration of less than 0.5 mg can produce a paradoxical bradycardia because of the central or peripheral parasympathomimatic effects of low dose in adults.
Conventional systemic doses may precipitate acute glaucoma in susceptible patients, convert partial organic pyloric stenosis into complete obstruction, lead to complete urinary retention in patients with prostatic hypertrophy or cause inspissation of bronchial secretions and formation of dangerous viscid plugs in patients with chronic lung disease.
See WARNINGS above
No laboratory tests in addition to routine tests are required.
Drug/Laboratory Test Interactions
None of note
Body as a Whole:
Dryness of the mouth, constipation
Blurred vision, dilated pupils, difficulty in swallowing, tremor,
Difficulty in micturition